Published in Blood Coagul Fibrinolysis on July 01, 1995
Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest (2001) 1.20
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest (2004) 1.17
Systemic coagulation parameters in mice after treatment with vascular targeting agents. Thromb J (2005) 0.78
Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog. Haemophilia (2011) 0.77
Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun (1990) 4.46
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int (2000) 4.43
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst (2000) 4.15
Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost (2000) 2.45
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40
Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest (1999) 2.34
Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development. EMBO J (1999) 2.27
Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost (2011) 2.18
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 2.11
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost (1994) 2.05
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem (1998) 1.84
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia (2004) 1.81
Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost (2003) 1.72
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Expression of an X-linked muscular dystrophy in a female due to translocation involving Xp21 and non-random inactivation of the normal X chromosome. Hum Genet (1984) 1.64
Restriction and modification in Bacillus subtilis: identification of a gene in the temperate phage SP beta coding for a BsuR specific modification methyltransferase. Mol Gen Genet (1980) 1.62
Letter: Factor-VIII complex and endothelial damage. Lancet (1975) 1.61
Disappearance rate of spermatozoa from the ejaculate following vasectomy. Fertil Steril (1969) 1.61
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol (2001) 1.59
Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol (1992) 1.56
The T3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production. EMBO J (1997) 1.54
A revised model of platelet aggregation. J Clin Invest (2000) 1.54
Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol (1990) 1.53
Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res (1991) 1.51
Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother (1989) 1.51
Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer (2003) 1.50
Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood (1978) 1.47
Embolic and bleeding events after modified Bentall procedure in selected patients. Heart (2006) 1.47
Selective advantage of fra (X) heterozygotes. Hum Genet (1990) 1.47
Validation of a live animal model for training in endoscopic hemostasis of upper gastrointestinal bleeding ulcers. Endoscopy (2013) 1.46
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis (1992) 1.45
Impaired sexual activity in young ischaemic stroke patients: an observational study. Eur J Neurol (2013) 1.43
Health-related quality of life in patients with melanoma expressed as utilities and disability weights. Br J Dermatol (2014) 1.42
The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA. RNA (2001) 1.42
Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr (1997) 1.42
A point mutation in a type I procollagen gene converts glycine 748 of the alpha 1 chain to cysteine and destabilizes the triple helix in a lethal variant of osteogenesis imperfecta. J Biol Chem (1987) 1.41
Headache after hematopoietic stem cell transplantation: being aware of chronic bilateral subdural hematoma. Leuk Lymphoma (2006) 1.40
Young investigators. FASEB J (1990) 1.40
The inhibition of the motility of human spermatozoa by various pharmacologic agents. Biol Reprod (1975) 1.35
An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest (1995) 1.33
Aspirin and recurrent painful toes and fingers in thrombocythaemia. Lancet (1972) 1.33
Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens (2001) 1.29
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Effects of (H + ), (Na + ), (K + ) and certain membrane-active drugs on glycolysis, motility, and ATP synthesis by human spermatozoa. Biol Reprod (1973) 1.28
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol (1994) 1.27
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors. Cell (1991) 1.25
Neonatal stroke involving the middle cerebral artery in term infants: clinical presentation, EEG and imaging studies, and outcome. Dev Med Child Neurol (1995) 1.24
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med (2010) 1.24
Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. Biochem Biophys Res Commun (1990) 1.24
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol (2005) 1.22
Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. Lymphology (2007) 1.22
Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol (2002) 1.19
In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol (1998) 1.18
[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]. Rev Neurol (Paris) (1982) 1.18
The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost (1996) 1.17
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation (2001) 1.17
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol (2010) 1.17
Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res (2000) 1.17
Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. Am J Hum Genet (2000) 1.16
Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifen. Eur J Cancer (2003) 1.15
Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function. Br J Haematol (1981) 1.15
Restriction and modification in Bacillus subtilis: two DNA methyltransferases with BsuRI specificity. I. Purification and physical properties. J Biol Chem (1981) 1.15
Renal vascular lesions in lupus nephritis. Medicine (Baltimore) (1997) 1.14
Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer (2004) 1.14
Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost (2009) 1.14
GM-2 gangliosidosis (Sandhoff's disease): two year follow-up by MRI. Neuroradiology (1994) 1.14
Arterial thrombosis and protein S deficiency. Thromb Haemost (1989) 1.13
Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem (1997) 1.13
ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood (2000) 1.12
Identification of transcripts initiated from an internal promoter in the c-erbA alpha locus that encode inhibitors of retinoic acid receptor-alpha and triiodothyronine receptor activities. Mol Endocrinol (1997) 1.12
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther (1997) 1.12
Effects of hypothyroidism on the structural development of the organ of Corti in the rat. Acta Otolaryngol (1982) 1.11
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia (2003) 1.11
The effects of blood transfusions on PCR DNA typing at the CSF1P0, TP0X, TH01, D1S80, HLA-DQA1, LDLR, GYPA, HBGG, D7S8 and GC loci. J Forensic Sci (1997) 1.11
Restriction and modification in Bacillus subtilis: two DNA methyltransferases with BsuRI specificity. II. Catalytic properties, substrate specificity, and mode of action. J Biol Chem (1981) 1.11
Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol (1995) 1.09
Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis (1987) 1.09
Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. Am J Pathol (1997) 1.09
Enhancement of enzymatic fibrinolysis with 2-MHz ultrasound and microbubbles. J Thromb Haemost (2004) 1.08
Efficiency of platelet adhesion to fibrinogen depends on both cell activation and flow. Biophys J (2000) 1.08
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol (1996) 1.07
Effects of lysophosphatidic acid on proliferation and cytosolic Ca++ of human adult vascular smooth muscle cells in culture. Thromb Res (1999) 1.07
Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med (1990) 1.07
Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxic lung injury. Role of cyclic guanosine 5'-monophosphate. Am J Respir Crit Care Med (1998) 1.07
High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol (2000) 1.07
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet (2001) 1.06
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg (1997) 1.06